GyPSii and Garmin Sign Global Multi-year Agreement for Location-Based Services and Social Networking

26th June 2008, Amsterdam, The Netherlands: GyPSii, the leading geo-location and mobile social networking provider, today announced it has entered into a multi-year worldwide agreement with Garmin®, the world’s global leader in satellite navigation.

Under the terms of the agreement, GyPSii will provide technology, products, worldwide data center infrastructure, development licenses, and GyPSii branding rights to Garmin, on a worldwide non-exclusive basis for a range of Garmin products. Garmin anticipates that future products will include friend finding applications that support the GyPSii-powered location-based social networking services platform. Read more: GyPSii and Garmin Sign Global Multi-year Agreement

June 25th

Archangel Diamond Corporation closes private placement offering of Subscription Receipts for gross proceeds, upon release from escrow, of US$172.4 million

/NOT FOR RELEASE IN THE UNITED STATES/

Archangel Diamond Corporation (\"Archangel\" or the \"Corporation\") (TSXV: AAD) is pleased to announce that it has closed the private placement offering (the \"Offering\") of subscription receipts (the \"Subscription Receipts\") described in the Corporation\'s news release issued on 3 June 2008. Archangel has issued 137,920,000 Subscription Receipts at a subscription price of US$1.25 per Subscription Receipt for gross proceeds of US$172,400,000. Read more: Archangel Diamond Corporation ( AAD )

June 25th

Medicago\'s H5N1 VLP Vaccine Demonstrates Cross-Reactivity Against Multiple Strains of Avian Flu in Key Ferret Animal Model

Medicago Inc. (TSX VENTURE: MDG) today announced additional positive results for the Company\\\\\\\'s H5N1 Avian Influenza VLP vaccine from a preclinical immunogenicity study performed in ferrets, the most predictive animal model for evaluating the effectiveness of influenza vaccines in humans. The Company\'s H5N1 VLP vaccine induced high levels of antibodies that neutralized strains of H5N1 circulating virus beyond the strain used to develop the original vaccine. Cross-reactivity was demonstrated against three of the deadliest strains of H5N1: the Turkey strain (clade 2.2), the Anhui strain (clade 2.3) and the Vietnam strain (clade 1).

\"These data further highlight the competitive advantages of our proprietary avian flu vaccine. Not only have we been able to demonstrate the efficacy of our vaccine at very low doses, we have now demonstrated that our vaccine offers broad protection against a variety of strains of this deadly virus,\" said Andy Sheldon, President and CEO of Medicago. Read more: Medicago Inc ( MDG )

June 25th

International Northair Intersects 120.4 Metres of 100.9 g/t Silver With Second Drill Program at El Reventon Project, Mexico

International Northair Mines Ltd. (TSX VENTURE:INM) (the \"Company\" or \"Northair\") is pleased to announce assay results from a second phase drill program recently completed at the El Reventon Project, located in the state of Durango, Mexico. The drill program, totaling 2,170 metres in 17 reverse circulation drill holes, was successful in further exploring and expanding the Reventon Breccia. The zone, which had no previous drilling until acquired by the Company in 2007, has now been tested by 21 drill holes.

Twelve of the 15 holes from the current program at the Reventon Breccia intersected significant silver values. Highlights include 91.4 metres of 87 g/t silver containing an intercept of 19.8 metres of 176.4 g/t sliver; and 80.8 metres of 71.9 g/t silver containing an intercept of 7.6 metres of 234.5 g/t silver. Results of the Company\'s second drill program are summarized in the following tables: Read more: International Northair Mines Ltd ( INM )